Explore 3 Stock Ideas & Industry Insights Download Free Report
● The 2026Revenueforecast rose to $115 million to $117 million.
● DoubleU Games holds roughly two-thirds of the company.
● The new drug application is on track for the first half of 2027.
● JPMorgan flagged promotional competition as a concern.
● Dole's update arrived as investors favored riskier stocks over defensive ones.
● Milestone payments could reach about $134 million.
● It has shipped over 8 million microinverters from US facilities.
Key Highlights● Eupraxia climbed on November 9 after RBC initiated coverage.● The rating is Outperform with a $14 price target.● The shares rose to about $6.89.● An interim EP-104GI readout is expected in December.A bullish first lookEupraxia Pharmaceuticals (NASDAQ:EPRX) climbed on Monday, November 9, …
● Shares were up by a double-digit amount at $23.18.
● Fervo highlighted a 396-megawatt power deal with Google.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…